Intersect ENT, Inc. Income Statement 2020-2011 | XENT

Brief overview of financial results at Intersect ENT, Inc.

The figures are compared over a five-year interval. Intersect ENT, Inc. reported revenue of $61.6 million in 2015 and $80.6 million by 2020. Overall revenue changed by +30.8%, equal to an annualized rate of about 5.5%. Sales increased steadily, although without strong acceleration.

Gross profit was 49.3 million dollars at the start and 50.2 million dollars at the end of the period (+1.9%). Gross profit as a share of revenue changed from 80% to 62.4%. The margin decline reflects a less favorable sales-and-cost structure.

The operating result measured by EBITDA moved from −26.1 million dollars to −64.8 million dollars, or −148.2%. EBITDA lagged revenue, showing weaker operating momentum. At the operating-margin level, the figure shifted from −42.4% to −80.5%. A lower EBITDA share weakens the quality of the result.

The net financial result changed from −$26.6 million to −$72.3 million. Profitability deteriorated further over the five years.

Over the period, capitalization shifted from 466 million dollars to 735 million dollars (+57.5%). Higher capitalization indicates improving investor confidence.

Summary assessment

The current trajectory does not yet confirm a sustainable recovery. Key strengths include revenue expansion. Caution is warranted because of a lower gross margin, a weaker final result and a declining EBITDA margin. Further direction will depend on top-line growth, operating profitability, and net income.